MedTrace Logo

DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA

NCT02413749 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2017-08-18

No results posted yet for this study

Summary

Biologics such as anti-Tumor Necrosis Factor or TNF inhibitor (TNFi) for treatment of Psoriatic Arthritis (PsA) has greatly reduced bone damage. This collaborative study will provide insights into key mechanisms that underlie inflammatory arthritis and bone damage in psoriatic joints and will catalyze biomarker discovery, identifying early biologic responders to facilitate optimization of therapy.

Conditions

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Christopher Ritchlin, MD/MPH · University of Rochester

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-13
Primary Completion
2016-12-28
Completion
2016-12-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02413749 on ClinicalTrials.gov